TELA BIO INC
TELANASDAQTrading Snapshot
- Day Range
- $1.23 – $1.26
- 52-Week Range
- $0.50 – $1.60
- Volume
- $2.96B
- Avg Volume
- $2.43B
- Shares Outstanding
- 44.7M
- Next Earnings
- Dec 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $80M
- Last Q Revenue
- $19M
- P/E Ratio
- -1.6
- P/S Ratio
- 0.7x
- EPS (TTM)
- $-0.72
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +29.0%
Why Investors Own TELA
- ✓High-growth profile — revenue up +40.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TELA BIO INC
TELA
StockOtter · stockotter.spaceAbout TELA BIO INC
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in Stock
TELA Bio, Inc. (NASDAQ: TELA - Get Free Report) Director Joseph Capper bought 25,000 shares of TELA Bio stock in a transaction that occurred on Thursday, September 17th. The shares were acquired at an average price of $1
TELA Bio (NASDAQ:TELA) versus Baxter International (NYSE:BAX) Head to Head Analysis
Baxter International (NYSE: BAX - Get Free Report) and TELA Bio (NASDAQ: TELA - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.22 per share a year ago.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announ